Skip to main content

Table 2 Primary and secondary outcomes

From: Routine administration of neostigmine after recovery of spontaneous breathing versus neuromuscular monitor-guided administration of neostigmine in pediatric patients: a parallel, randomized, controlled study

Outcomes

Experimental group (n=60)

Control group (n=60)

Effect estimated (95% CI)

p-value

Primary outcomes

 Cases of rNMB after extubation (TOF ratio <0.9), n (%)

45 (75.0)

44 (73.3)

1.02 (0.83 to 1.26)a

0.84

 Cases of patients with TOF ratio < 0.3, n (%)

12 (20)

0 (0)

31.12 (1.89 to 512.61)a

0.00

Secondary outcomes

 Cases of neostigmine-induced muscle paralysis, n (%)

0 (0)

0 (0)

-

-

 End of surgery – extubation interval (min), mean±SD

8.9 ± 5.1

9.6 ± 4.5

−0.70 (−2.42 to 1.02)b

0.40

 End of surgery – exit OR interval (min), mean±SD

13.6 ± 5.2

15.7 ± 5.6

−2.10 (−3.70 to −0.50)b

0.04

 The length of stay in the PACU (min), mean±SD

45.1 ± 15.6

46.0 ± 13.5

−0.90 (−6.12 to 4.32)b

0.73

 Cases of hypoxia, n (%)

  In OR

2 (3.3)

1(1.7)

2.00 (0.19 to 21.47)a

0.56

  In PACU

0 (0)

0 (0)

-

-

 Cases of children who required assisted ventilation, n (%)

  In OR

2 (3.3)

1 (1.7)

2.00 (0.19 to 21.47)a

0.56

  In PACU

0 (0)

0 (0)

-

-

 Cases of bradycardia, n (%)

  In OR

0 (0)

0 (0)

-

-

  In PACU

0 (0)

0 (0)

-

-

 Cases of nausea and vomiting, n (%)

  In PACU

0 (0)

0 (0)

-

-

  On the first postoperative day

1 (1.7)

0 (0)

3.00 (0.12 to 72.20)a

0.32

  1. rNMB residual neuromuscular blockade, min minute, OR operating room, PACU postanesthesia care unit
  2. aEffect estimated is the risk ratio (RR)
  3. bEffect estimated is the mean difference (MD)